Filtered By:
Condition: Hypertension
Drug: Cozaar
Procedure: Electrocardiogram

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 3 results found since Jan 2013.

Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy
Conclusion: Abnormal PTFV1, a marker of left atrial abnormality, was strongly associated with incident stroke in hypertensive patients, independent of in-treatment SBP and other predictors of incident stroke. This association, in the absence of detectable atrial fibrillation, suggests that an underlying atrial cardiopathy may cause left atrial thrombus formation and a subsequent stroke without intervening clinically recognized atrial fibrillation.
Source: Journal of Hypertension - August 5, 2016 Category: Cardiology Tags: ORIGINAL PAPERS: Heart Source Type: research

Mitral Annular Calcification and Incident Ischemic Stroke in Treated Hypertensive Patients: The LIFE study.
ConclusionsMAC is common in treated hypertensive patients with ECG LVH and is an independent predictor of incident ischemic stroke. PMID: 23391619 [PubMed - as supplied by publisher]
Source: American Journal of Hypertension - February 7, 2013 Category: Cardiology Authors: De Marco M, Gerdts E, Casalnuovo G, Migliore T, Wachtell K, Boman K, Dahlöf B, Olsen MH, Kizer JR, Devereux RB, de Simone G Tags: Am J Hypertens Source Type: research

Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.
Authors: Mancusi C, Gerdts E, de Simone G, Midtbø H, Lønnebakken MT, Boman K, Wachtell K, Dahlöf B, Devereux RB Abstract We tested the prognostic impact of a marker of arterial stiffness, pulse pressure/stroke volume index (PP/SVi) in patients with hypertension and left ventricular (LV) hypertrophy. We used data from 866 patients randomized to losartan or atenolol-based antihypertensive treatment, over a median of 4.8 years, in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. The association of PP/SVi with outcomes was tested in Cox regression analyses and reported as hazard ratio (...
Source: Blood Pressure - October 7, 2016 Category: Hematology Tags: Blood Press Source Type: research